Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH

Section 32 led Glympse's series B round, which will also fund clinical testing of an oncology program

With $47.6 million in new series B cash, Glympse will conduct an authorization-enabling study designed to show its synthetic biosensor can determine disease severity and track treatment response in patients with non-alcoholic steatohepatitis.

The company hopes its most advanced biosensor program can reliably produce data about disease states and interventions earlier than invasive liver biopsies, President and CEO Caroline Loew

Read the full 602 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE